%0 Journal Article
%A Blobner, Jens
%A Ruf, Viktoria
%A Weller, Jonathan
%A Teske, Nico
%A Forbrig, Robert
%A Thon, Niklas
%A Albert, Nathalie L
%A von Baumgarten, Louisa
%A Schoenecker, Stephan
%A Tonn, Joerg-Christian
%A Ringel, Florian
%A Harter, Patrick
%A Karschnia, Philipp
%T Clinical and neuropathological criteria for distinguishing between IDH-mutant astrocytomas of WHO grade 2 and 3.
%J Journal of neuro-oncology
%V 175
%N 2
%@ 0167-594X
%C Dordrecht [u.a.]
%I Springer Science + Business Media B.V
%M DKFZ-2025-01505
%P 763-774
%D 2025
%Z 2025 Nov;175(2):763-774
%X The 2021 WHO classification of CNS tumors allows flexibility in the grading of IDH-mutant astrocytic gliomas, leading to some ambiguity. Following the approval of vorasidenib for WHO grade 2 astrocytomas and oligodendrogliomas based on the positive Phase III INDIGO trial, identifying prognostic criteria to differentiate between grade 2 and grade 3 tumors has become increasingly important.We retrospectively searched our institutional database for patients meeting the diagnostic criteria for IDH-mutant astrocytomas (grade 2 and 3) according to the WHO 2021 classification. Clinical, radiological and molecular data were collected; outcome was compared using log-rank analysis and prognostic markers were subsequently forwarded in a multivariate model.We identified 91 patients with IDH-mutant astrocytomas with available neuropathological and clinical data, including 61 WHO grade 2 (67.0
%K Astrocytoma (Other)
%K Contrast-enhancement (Other)
%K Grading (Other)
%K IDH-inhibitor (Other)
%K IDH-mutant (Other)
%K Mitotic count (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40702387
%R 10.1007/s11060-025-05173-z
%U https://inrepo02.dkfz.de/record/303080